HC Wainwright Reaffirms Buy Rating for Tarsus Pharmaceuticals (NASDAQ:TARS)

HC Wainwright restated their buy rating on shares of Tarsus Pharmaceuticals (NASDAQ:TARS) in a report issued on Wednesday,Benzinga reports. They currently have a $73.00 target price on the stock.

Several other brokerages have also recently issued reports on TARS. Oppenheimer upped their price objective on Tarsus Pharmaceuticals from $65.00 to $72.00 and gave the company an “outperform” rating in a research note on Wednesday, January 22nd. The Goldman Sachs Group boosted their price objective on shares of Tarsus Pharmaceuticals from $36.00 to $41.00 and gave the company a “neutral” rating in a research report on Friday, November 15th. Guggenheim reiterated a “buy” rating and set a $78.00 price objective (up previously from $75.00) on shares of Tarsus Pharmaceuticals in a research note on Monday. Finally, Barclays lifted their target price on Tarsus Pharmaceuticals from $60.00 to $62.00 and gave the company an “overweight” rating in a research note on Monday, January 27th. One analyst has rated the stock with a hold rating, five have assigned a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat.com, Tarsus Pharmaceuticals currently has a consensus rating of “Buy” and a consensus price target of $61.33.

Tarsus Pharmaceuticals Trading Up 3.1 %

TARS opened at $42.56 on Wednesday. The firm has a market capitalization of $1.63 billion, a P/E ratio of -11.17 and a beta of 1.01. The firm’s 50 day moving average is $51.31 and its 200-day moving average is $43.00. The company has a quick ratio of 5.38, a current ratio of 5.42 and a debt-to-equity ratio of 0.30. Tarsus Pharmaceuticals has a 52-week low of $20.08 and a 52-week high of $57.28.

Tarsus Pharmaceuticals (NASDAQ:TARS) last posted its quarterly earnings data on Tuesday, February 25th. The company reported ($0.60) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.68) by $0.08. Tarsus Pharmaceuticals had a negative net margin of 103.64% and a negative return on equity of 55.86%. The company had revenue of $66.41 million during the quarter, compared to analysts’ expectations of $58.80 million. Analysts expect that Tarsus Pharmaceuticals will post -3.17 EPS for the current fiscal year.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently bought and sold shares of TARS. Toronto Dominion Bank bought a new stake in shares of Tarsus Pharmaceuticals during the fourth quarter valued at approximately $105,714,000. GF Fund Management CO. LTD. bought a new position in Tarsus Pharmaceuticals in the 4th quarter worth approximately $44,000. Nationale Nederlanden Powszechne Towarzystwo Emerytalne S.A. acquired a new stake in Tarsus Pharmaceuticals in the 4th quarter valued at approximately $3,278,000. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC raised its stake in Tarsus Pharmaceuticals by 18.7% during the 4th quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 69,826 shares of the company’s stock valued at $3,866,000 after acquiring an additional 10,991 shares in the last quarter. Finally, Woodline Partners LP boosted its position in Tarsus Pharmaceuticals by 52.3% during the 4th quarter. Woodline Partners LP now owns 108,986 shares of the company’s stock worth $6,035,000 after acquiring an additional 37,417 shares during the period. Institutional investors own 90.01% of the company’s stock.

About Tarsus Pharmaceuticals

Tarsus Pharmaceuticals, Inc, a commercial stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutic candidates for eye care in the United States. The company's lead product candidate is XDEMVY, a novel therapeutic for the treatment of blepharitis caused by the infestation of Demodex mites, as well as to treat meibomian gland disease.